Judgment of the National Green Tribunal in the matter of Shalbjit Singh Vs Punjab State Pollution Control Board & Others dated 21/11/2024. A letter petition dated November 5, 2022 was sent by Shalabhjeet Singh, resident of village Haibatpur, tehsil Derabassi, district SAS Nagar, Mohali complaining that M/s Nectar Life Sciences …
It's double trouble for global pharma companies in India. On April 1, a Supreme Court bench comprising Judges Aftab Alam and Ranjana Desai dismissed Swiss drug major Novartis AG's seven-year-old plea seeking patent protection for its blood cancer drug Imatinib Mesylate, sold as Glivec. The court held that Glivec was …
Companies say they follow global standards in India as well Drug majors such as Novartis, Pfizer, Bayer Healthcare, Bristol Mayer Squibb, Sun Pharmaceutical and Dr Reddy’s Laboratories were allegedly involved in clinical trials in which 438 persons died in 2011, according to confidential government data reviewed by Business Standard. While …
German pharmaceutical company Bayer AG has formally lodged a challenge against a landmark Indian ruling that allowed a domestic generic drug-maker to produce a low-cost version of an anti-cancer drug for the Indian market. The appeal was filed on Friday 4 May with India's Intellectual Property Appellate Board.
The compulsory licence issued to Natco for manufacture of the anti-cancer drug Nexavar is a landmark decision on many grounds – the first one in India since the 2005 amendment to the 1970 Patents Act and the fi rst in the world issued to a private party. There are some …
In a landmark move, the Indian Patent Office announced on Monday that it has issued its first compulsory license to a domestic generic drug-maker. The decision effectively ends German pharmaceutical company Bayer AG's monopoly over an anti-cancer drug and authorises the production of a low-cost version for the Indian market.
The government today asserted India would invoke the flexibility it had under the WTO agreement on Trade Related Intellectual Property Rights (TRIPs) for compulsory licensing of patented drugs to ensure availability of life saving drugs at affordable prices to its people. The Controller General of Patents, Designs and Trademarks had …
Mumbai: In a landmark decision that could set a precedent on how life-saving drugs under patents can be made affordable, the government has allowed a domestic company, Natco Pharma, to manufacture a copycat version of Bayer’s patented anti-cancer drug, Nexavar, bringing down its price by 97 %.. In the first-ever …
GERMAN drugmaker Bayer has filed a patent infringement case against Cipla, the largest domestic drugseller, to stop the Mumbaibased company from selling its generic version of Bayer
The Delhi High Court refused a patent linkage to multinational pharma company Bayer’s for its cancer drug sorefenib tosylate, sold under the name Nexavar. This means there is no restriction on the drug controller to approve generic versions of patent drugs. Bayer holds the patent for sorenfenib, used to treat …
Delhi HC Ruling Big Victory For Indian Drugmakers IN A major win for Indian pharma companies, the Delhi High Court (HC) on Tuesday dismissed German drug major Bayer Healthcare
The press release by Greenpeace on its protest against herbicide-resistant rice trial by Bayer Crop in the village of Chinnakanjarla, about 45 kilometers from Hyderabad in Andhra Pradesh. It warns that this would lead to serious contamination of non-GM rice grown in the vicinity. Greenpeace activists today raided a genetically …
